

MEDICAL PROPERTIES TRUST INC
Form 8-K
August 14, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): August 12, 2015

MEDICAL PROPERTIES TRUST, INC.
MPT OPERATING PARTNERSHIP, L.P.
(Exact Name of Registrant as Specified in Charter)

Maryland	001-32559	20-0191742
Delaware (State or other jurisdiction of	333-177186 (Commission	20-0242069 (I.R.S. Employer

Item 8.01. Other Events.

On August 12, 2015, the operating partnership of Medical Properties Trust, Inc., a Maryland corporation (the Company), MPT Operating Partnership, L.P., a Delaware limited partnership (the Operating Partnership), MPT Finance Corporation, a Delaware corporation and wholly owned subsidiary of the Operating Partnership (MPT Finance), and together with the Operating Partnership, the Issuers), and the Company, as guarantor, entered into an underwriting agreement (the Underwriting Agreement) with Goldman, Sachs & Co., Crédit Agricole Corporate and Investment Bank, Credit Suisse Securities (Europe) Limited and J.P. Morgan Securities plc as representatives of the several underwriters named therein (collectively, the Underwriters), pursuant to which the Issuers agreed to issue and sell to the Underwriters 500,000,000 aggregate principal amount of the Issuers 4.00% Senior Notes due 2022 (the Notes). The offering of the Notes is expected to close on or about August 19, 2015, subject to customary closing conditions.

The Notes are fully and unconditionally guaranteed on an unsecured basis by the Company.

The offering and sale of the Notes was made pursuant to a free writing prospectus, preliminary prospectus supplement and final prospectus supplement pursuant to the Issuers and the Company's effective registration statement on Form S-3 (File No. 333-190543), each of which has been filed with the Securities and Exchange Commission.

The Underwriting Agreement contains customary representations, warranties and covenants by the Issuers and the Company. It also provides for customary indemnification by each of the Issuers and the Company for losses or damages arising out of or in connection with the sale of the Notes.

The foregoing is a summary description of certain terms of the Underwriting Agreement and is qualified in its entirety by the text of the Underwriting Agreement attached as Exhibit 1.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit

No.	Description
1.1	Underwriting Agreement, dated August 12, 2015, among the Issuers, the Company and Goldman, Sachs & Co., Crédit Agricole Corporate and Investment Bank, Credit Suisse Securities (Europe) Limited and J.P. Morgan Securities plc, as representatives of the several underwriters named therein
5.1	Opinion of Goodwin Procter LLP regarding legality of senior notes offered
23.1	Consent of Goodwin Procter LLP (included in Exhibit 5.1)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDICAL PROPERTIES TRUST, INC.

(Registrant)

By: /s/ R. Steven Hamner
R. Steven Hamner
Executive Vice President and Chief
Financial Officer

(Principal Financial and Accounting
Officer)

MPT OPERATING PARTNERSHIP, L.P.

(Registrant)

By: /s/ R. Steven Hamner
R. Steven Hamner
Executive Vice President and Chief
Financial Officer of the sole member of
the general partner of MPT Operating
Partnership, L.P.

Date: August 14, 2015

INDEX TO EXHIBITS

Exhibit No.	Description
1.1	Underwriting Agreement, dated August 12, 2015, among the Issuers, the Company and Goldman, Sachs & Co., Crédit Agricole Corporate and Investment Bank, Credit Suisse Securities (Europe) Limited and J.P. Morgan Securities plc, as representatives of the several underwriters named therein
5.1	Opinion of Goodwin Procter LLP regarding legality of senior notes offered
23.1	Consent of Goodwin Procter LLP (included in Exhibit 5.1)